{"doi":"10.1002\/gps.2607","coreId":"217780","oai":"oai:eprints.lse.ac.uk:32647","identifiers":["oai:eprints.lse.ac.uk:32647","10.1002\/gps.2607"],"title":"Determining the minimum clinically important differences for outcomes in the DOMINO trial","authors":["Howard, Robert","Phillips, Patrick","Johnson, Tony","O'Brien, John T.","Sheehan, Bart","Lindesay, James","Bentham, Peter","Burns, Alistair S.","Ballard, Clive G.","Holmes, Clive","McKeith, Ian","Barber, Robert","Dening, Tom","Ritchie, Craig","Jones, Rob","Baldwin, Ashley","Passmore, Peter","Findlay, David","Hughes, Alan","Macharouthu, Ajay","Banerjee, Sube","Jones, Roy W.","Knapp, Martin","Brown, Richard G.","Jacoby, Robin","Adams, Jessica","Griffin, Mary","Gray, Richard"],"enrichments":{"references":[],"documentType":{"type":null}},"contributors":[],"datePublished":"2011-08","abstract":"Background\\ud\nAlthough less likely to be reported in clinical trials than expressions of the statistical significance of differences in outcomes, whether or not a treatment has delivered a specified minimum clinically important difference (MCID) is also relevant to patients and their caregivers and doctors. Many dementia treatment randomised controlled trials (RCTs) have not reported MCIDs and, where they have been done, observed differences have not reached these.\\ud\n\\ud\nMethods\\ud\nAs part of the development of the Statistical Analysis Plan for the DOMINO trial, investigators met to consider expert opinion- and distribution-based values for the MCID and triangulated these to provide appropriate values for three outcome measures, the Standardised Mini-mental State Examination (sMMSE), Bristol Activities of Daily Living Scale (BADLS) and Neuropsychiatric Inventory (NPI). Only standard deviations (SD) were presented to investigators who remained blind to treatment allocation.\\ud\n\\ud\nResults\\ud\nAdoption of values for MCIDs based upon 0.4 of the SD of the change in score from baseline on the sMMSE, BADLS and NPI in the first 127 participants to complete DOMINO yielded MCIDs of 1.4 points for sMMSE, 3.5 for BADLS and 8.0 for NPI.\\ud\n\\ud\nConclusions\\ud\nReference to MCIDs is important for the full interpretation of the results of dementia trials and those conducting such trials should be open about the way in which they have determined and chosen their values for the MCIDs","downloadUrl":"","fullTextIdentifier":null,"pdfHashValue":null,"publisher":"Wiley","rawRecordXml":"<record><header><identifier>\n    \n    \n      oai:eprints.lse.ac.uk:32647<\/identifier><datestamp>\n      2012-01-30T13:30:40Z<\/datestamp><setSpec>\n      74797065733D4445505453:4C53452D5341<\/setSpec><setSpec>\n      74797065733D43454E54524553:4C53455F52435F3536<\/setSpec><\/header><metadata><oai_dc:dc xmlns:oai_dc=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/\" xmlns:dc=\"http:\/\/purl.org\/dc\/elements\/1.1\/\" xmlns:xsi=\"http:\/\/www.w3.org\/2001\/XMLSchema-instance\" xsi:schemaLocation=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/ http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc.xsd\" ><dc:relation>\n    \n      \n        http:\/\/eprints.lse.ac.uk\/32647\/<\/dc:relation><dc:title>\n        Determining the minimum clinically important differences for outcomes in the DOMINO trial<\/dc:title><dc:creator>\n        Howard, Robert<\/dc:creator><dc:creator>\n        Phillips, Patrick<\/dc:creator><dc:creator>\n        Johnson, Tony<\/dc:creator><dc:creator>\n        O'Brien, John T.<\/dc:creator><dc:creator>\n        Sheehan, Bart<\/dc:creator><dc:creator>\n        Lindesay, James<\/dc:creator><dc:creator>\n        Bentham, Peter<\/dc:creator><dc:creator>\n        Burns, Alistair S.<\/dc:creator><dc:creator>\n        Ballard, Clive G.<\/dc:creator><dc:creator>\n        Holmes, Clive<\/dc:creator><dc:creator>\n        McKeith, Ian<\/dc:creator><dc:creator>\n        Barber, Robert<\/dc:creator><dc:creator>\n        Dening, Tom<\/dc:creator><dc:creator>\n        Ritchie, Craig<\/dc:creator><dc:creator>\n        Jones, Rob<\/dc:creator><dc:creator>\n        Baldwin, Ashley<\/dc:creator><dc:creator>\n        Passmore, Peter<\/dc:creator><dc:creator>\n        Findlay, David<\/dc:creator><dc:creator>\n        Hughes, Alan<\/dc:creator><dc:creator>\n        Macharouthu, Ajay<\/dc:creator><dc:creator>\n        Banerjee, Sube<\/dc:creator><dc:creator>\n        Jones, Roy W.<\/dc:creator><dc:creator>\n        Knapp, Martin<\/dc:creator><dc:creator>\n        Brown, Richard G.<\/dc:creator><dc:creator>\n        Jacoby, Robin<\/dc:creator><dc:creator>\n        Adams, Jessica<\/dc:creator><dc:creator>\n        Griffin, Mary<\/dc:creator><dc:creator>\n        Gray, Richard<\/dc:creator><dc:subject>\n        RA Public aspects of medicine<\/dc:subject><dc:description>\n        Background\\ud\nAlthough less likely to be reported in clinical trials than expressions of the statistical significance of differences in outcomes, whether or not a treatment has delivered a specified minimum clinically important difference (MCID) is also relevant to patients and their caregivers and doctors. Many dementia treatment randomised controlled trials (RCTs) have not reported MCIDs and, where they have been done, observed differences have not reached these.\\ud\n\\ud\nMethods\\ud\nAs part of the development of the Statistical Analysis Plan for the DOMINO trial, investigators met to consider expert opinion- and distribution-based values for the MCID and triangulated these to provide appropriate values for three outcome measures, the Standardised Mini-mental State Examination (sMMSE), Bristol Activities of Daily Living Scale (BADLS) and Neuropsychiatric Inventory (NPI). Only standard deviations (SD) were presented to investigators who remained blind to treatment allocation.\\ud\n\\ud\nResults\\ud\nAdoption of values for MCIDs based upon 0.4 of the SD of the change in score from baseline on the sMMSE, BADLS and NPI in the first 127 participants to complete DOMINO yielded MCIDs of 1.4 points for sMMSE, 3.5 for BADLS and 8.0 for NPI.\\ud\n\\ud\nConclusions\\ud\nReference to MCIDs is important for the full interpretation of the results of dementia trials and those conducting such trials should be open about the way in which they have determined and chosen their values for the MCIDs.<\/dc:description><dc:publisher>\n        Wiley<\/dc:publisher><dc:date>\n        2011-08<\/dc:date><dc:type>\n        Article<\/dc:type><dc:type>\n        PeerReviewed<\/dc:type><dc:identifier>\n          Howard, Robert and Phillips, Patrick and Johnson, Tony and O'Brien, John T. and Sheehan, Bart and Lindesay, James and Bentham, Peter and Burns, Alistair S. and Ballard, Clive G. and Holmes, Clive and McKeith, Ian and Barber, Robert and Dening, Tom and Ritchie, Craig and Jones, Rob and Baldwin, Ashley and Passmore, Peter and Findlay, David and Hughes, Alan and Macharouthu, Ajay and Banerjee, Sube and Jones, Roy W. and Knapp, Martin and Brown, Richard G. and Jacoby, Robin and Adams, Jessica and Griffin, Mary and Gray, Richard  (2011) Determining the minimum clinically important differences for outcomes in the DOMINO trial.  International Journal of Geriatric Psychiatry, 26 (8).  pp. 812-817.  ISSN 0885-6230     <\/dc:identifier><dc:relation>\n        http:\/\/dx.doi.org\/10.1002\/gps.2607<\/dc:relation><dc:relation>\n        10.1002\/gps.2607<\/dc:relation><\/oai_dc:dc><\/metadata><\/record>","journals":null,"language":null,"relations":["http:\/\/eprints.lse.ac.uk\/32647\/","http:\/\/dx.doi.org\/10.1002\/gps.2607","10.1002\/gps.2607"],"year":2011,"topics":["RA Public aspects of medicine"],"subject":["Article","PeerReviewed"],"fullText":null}